According to a new report LAMEA Antibiotics Market, published by KBV research, the LAMEA Antibiotics Market would witness market growth of 6.2% CAGR during the forecast period (2020-2026).
The Brazil market dominated the LAMEA Carbapenem Market by Country in 2019, thereby, achieving a market value of $122.9 million by 2026. The Argentina market would witness a CAGR of 7.9% during (2020 - 2026). Additionally, The UAE market is experiencing a CAGR of 6.6% during (2020 - 2026).
The Cell Wall Synthesis Inhibitors market dominated the Saudi Arabia Antibiotics Market by Action Mechanism in 2019, growing at a CAGR of 4.9 % during the forecast period. The Protein Synthesis Inhibitors market is exhibiting a CAGR of 5.5% during (2020 - 2026). Additionally, The Others market is expected to witness highest CAGR of 11.8% during (2020 - 2026).
The Cephalosporin market dominated the South Africa Antibiotics Market by Drug Class in 2019, growing at a CAGR of 5.1 % during the forecast period. The Penicillin market is estimated to grow at a CAGR of 5% during (2020 - 2026). The Fluoroquinolone market would showcase a CAGR of 7.8% during (2020 - 2026). Additionally, The Macrolides market is expected to witness highest CAGR of 7.9% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/lamea-antibiotics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
By Action Mechanism
By Drug Class
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
